Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.

Kindler HL.

Lung Cancer. 2004 Aug;45 Suppl 1:S125-7. Review.

PMID:
15261445
2.

New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.

Nowak AK, Lake RA, Kindler HL, Robinson BW.

Semin Oncol. 2002 Feb;29(1):82-96. Review.

PMID:
11836673
3.

Molecularly targeted therapy for gastrointestinal cancer.

Wiedmann MW, Caca K.

Curr Cancer Drug Targets. 2005 May;5(3):171-93. Review.

PMID:
15892618
4.

Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation.

Nykänen AI, Krebs R, Tikkanen JM, Raisky O, Sihvola R, Wood J, Koskinen PK, Lemström KB.

Transplantation. 2005 Jan 27;79(2):182-9.

PMID:
15665766
5.

Platelet-derived growth factor receptors: a therapeutic target in solid tumors.

George D.

Semin Oncol. 2001 Oct;28(5 Suppl 17):27-33. Review.

PMID:
11740804
6.

Molecular targets in malignant pleural mesothelioma treatment.

Pasello G, Favaretto A.

Curr Drug Targets. 2009 Dec;10(12):1235-44. Review.

PMID:
19909234
8.
9.
10.

Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.

Porta C, Mutti L, Tassi G.

Cancer Chemother Pharmacol. 2007 Jan;59(1):149-50. Epub 2006 Apr 25. No abstract available.

PMID:
16636799
11.

Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease.

Tikkanen JM, Hollmén M, Nykänen AI, Wood J, Koskinen PK, Lemström KB.

Am J Respir Crit Care Med. 2006 Nov 15;174(10):1145-52. Epub 2006 Aug 17.

PMID:
16917119
12.

New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID:
15655420
13.

Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.

Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.

Cancer Res. 2005 Mar 1;65(5):1897-903.

14.

Imatinib-induced regression of AIDS-related Kaposi's sarcoma.

Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ.

J Clin Oncol. 2005 Feb 10;23(5):982-9. Epub 2004 Nov 30.

PMID:
15572730
15.

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.

Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM.

Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. Epub 2005 Sep 20.

PMID:
16172907
16.

The effect of imatinib mesylate (Glivec) on human tumor-derived cells.

Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.

Anticancer Drugs. 2006 Jul;17(6):649-55.

PMID:
16917210
17.

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

Press MF, Lenz HJ.

Drugs. 2007;67(14):2045-75. Review.

PMID:
17883287
18.

Translational therapies for malignant pleural mesothelioma.

Belli C, Anand S, Tassi G, Fennell D, Mutti L.

Expert Rev Respir Med. 2010 Apr;4(2):249-60. doi: 10.1586/ers.10.17. Review.

PMID:
20406091
19.

Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).

Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.

J Cutan Pathol. 2006 Apr;33(4):280-5.

PMID:
16630177
20.

Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.

McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6727-34.

Supplemental Content

Support Center